Literature DB >> 24977751

Never-frozen liquid plasma blocks endothelial permeability as effectively as thawed fresh frozen plasma.

Yanna Cao1, Anahita Dua, Nena Matijevic, Yao-Wei Wang, Shibani Pati, Charles E Wade, Tien C Ko, John B Holcomb.   

Abstract

BACKGROUND: Thawed fresh frozen plasma (TP) is a preferred plasma product for resuscitation but can only be used for up to 5 days after thawing. Never-frozen, liquid plasma (LQP) is approved for up to 26 days when stored at 1°C to 6°C. We have previously shown that TP repairs tumor necrosis factor α (TNF-α)-induced permeability in human endothelial cells (ECs). We hypothesized that stored LQP repairs permeability as effectively as TP.
METHODS: Three single-donor LQP units were pooled. Aliquots were frozen, and samples were thawed on Day 0 (TP0) then refrigerated for 5 days (TP5). The remaining LQP was kept refrigerated for 28 days, and aliquots were analyzed every 7 days. The EC monolayer was stimulated with TNF-α (10 ng/mL), inducing permeability, followed by a treatment with TP0, TP5, or LQP aged 0, 7, 14, 21, and 28 days. Permeability was measured by leakage of fluorescein isothiocyanate-dextran through the EC monolayer. Hemostatic profiles of samples were evaluated by thrombogram and thromboelastogram. Statistical analysis was performed using two-way analysis of variance, with p < 0.05 deemed significant.
RESULTS: TNF-α increased permeability of the EC monolayer twofold compared with medium control. There was a significant decrease in permeability at 0, 7, 14, 21, and 28 days when LQP was used to treat TNF-α-induced EC monolayers (p < 0.001). LQP was as effective as TP0 and TP5 at reducing permeability. Stored LQP retained the capacity to generate thrombin and form a clot.
CONCLUSION: LQP corrected TNF-α-induced EC permeability and preserved hemostatic potential after 28 days of storage, similar to TP stored for 5 days. The significant logistical benefit (fivefold) of prolonged LQP storage improves the immediate availability of plasma as a primary resuscitative fluid for bleeding patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24977751     DOI: 10.1097/TA.0000000000000276

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  5 in total

1.  Combat: Initial Experience with a Randomized Clinical Trial of Plasma-Based Resuscitation in the Field for Traumatic Hemorrhagic Shock.

Authors:  Michael P Chapman; Ernest E Moore; Theresa L Chin; Arsen Ghasabyan; James Chandler; John Stringham; Eduardo Gonzalez; Hunter B Moore; Anirban Banerjee; Christopher C Silliman; Angela Sauaia
Journal:  Shock       Date:  2015-08       Impact factor: 3.454

2.  Adiponectin in Fresh Frozen Plasma Contributes to Restoration of Vascular Barrier Function After Hemorrhagic Shock.

Authors:  Xiyun Deng; Yanna Cao; Maria P Huby; Chaojun Duan; Lisa Baer; Zhanglong Peng; Rosemary A Kozar; Marie-Francoise Doursout; John B Holcomb; Charles E Wade; Tien C Ko
Journal:  Shock       Date:  2016-01       Impact factor: 3.454

3.  Overwhelming tPA release, not PAI-1 degradation, is responsible for hyperfibrinolysis in severely injured trauma patients.

Authors:  Michael P Chapman; Ernest E Moore; Hunter B Moore; Eduardo Gonzalez; Fabia Gamboni; James G Chandler; Sanchayita Mitra; Arsen Ghasabyan; Theresa L Chin; Angela Sauaia; Anirban Banerjee; Christopher C Silliman
Journal:  J Trauma Acute Care Surg       Date:  2016-01       Impact factor: 3.313

4.  Identification of Fibrinogen as a Key Anti-Apoptotic Factor in Human Fresh Frozen Plasma for Protecting Endothelial Cells In Vitro.

Authors:  Qiang Yu; Baibing Yang; Joy M Davis; Jean Ghosn; Xiyun Deng; Marie-Francoise Doursout; Jing-Fei Dong; Run Wang; John B Holcomb; Charles E Wade; Tien C Ko; Yanna Cao
Journal:  Shock       Date:  2020-05       Impact factor: 3.533

Review 5.  Targeting repair of the vascular endothelium and glycocalyx after traumatic injury with plasma and platelet resuscitation.

Authors:  Mark Barry; Shibani Pati
Journal:  Matrix Biol Plus       Date:  2022-03-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.